Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.

Poor clinical, ultrasonographic responses seen in obese RA patients treated with ADA, MTX

22 Dec 2018
Under new NHS criteria, obese patients “will not get non-urgent surgery until they reduce their weight”.

Clinical and ultrasonographic responses are worse in obese vs nonobese patients with rheumatoid arthritis (RA) treated with adalimumab (ADA) and methotrexate (MTX), suggests a recent study, adding that these are partly overcome with time.

“Obese patients may experience better and faster clinical improvements if ADA is initiated with high-dose (20 mg/week) rather than low-dose MTX,” the authors said.

This posthoc analysis of the MUSICA trial examined MTX 20 mg/week vs 7.5 mg/week in combination with ADA in RA patients with an inadequate response to MTX. The authors categorized patients by baseline body mass index as normal (<25 kg/m2), overweight (≥25 to <30 kg/m2), or obese (≥ 30 kg/m2).

The following were evaluated at weeks 12 and 24: synovial vascularity and hypertrophy, swollen (SJC) and tender joint counts (TJC), American College of Rheumatology (ACR) responses, and low disease activity (LDA), defined as Clinical Disease Activity Index <10 and 28-joint count Disease Activity Score using C-reactive protein (DAS28-CRP) <3.2.

There were similar patient characteristics at baseline among groups. From baseline to weeks 12 and 24, changes in SJC, TJC, DAS28-CRP, and synovial hypertrophy and vascularity were numerically smaller in obese vs nonobese patients.

There were significantly fewer obese patients who reached ACR20/50 at weeks 12 and 24, and LDA at week 12. This difference was particularly evident among those receiving 7.5 mg/week MTX but was no longer significant at week 24.

Obese patients with RA report more joint swelling and tenderness and often have poorer responses to therapy than nonobese patients,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.